Efficacy and safety of dapagliflozin in the background of polypharmacy among patients with HFmrEF and HFpEF in the DELIVER trial

20 May 2023 (08:00 - 20:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Assistant Professor Alexander Peikert

Medical University of Graz, Graz (Austria)

7 More presentations in this session

Presentation thumbnail

Temporal trend in diuretic use in patients with heart failure with reduced ejection fraction on sacubitril/valsartan

Doctor D. Jain (Dublin, IE)

Abstract Slides

Presentation thumbnail

Loop diuretic down titration at discharge in patients hospitalized for acute heart failure

Doctor F. Croset (Madrid, ES)

Abstract Slides

Presentation thumbnail

Real-world analysis of heart failure medication before and after hospitalization for heart failure. Data from two large cohorts in the US and Germany.

Doctor A. Michel (Basel, CH)

Abstract Slides

Presentation thumbnail

Changes in NT-proBNP following patiromer-facilitated optimisation of RAASi in patients with HFrEF with current or recent hyperkalaemia: a post hoc analysis of the DIAMOND study

Professor L. Lund (Stockholm, SE)

Abstract Slides

Presentation thumbnail

Benefit of furher medical uptitration in heart failure with improved ejection fraction

Doctor P. Puwatnuttasit (Bangkok, TH)

Abstract Slides

Access the full session

Session thumbnail

Chronic heart failure - pharmacotherapy 4

The Event

Event poster

Heart Failure 2023

20 May - 23 May 2023

You may be interested in

Congress Presentation

Breaking the barriers in guideline-directed medical therapy implementation in heart failure - discussion

Congress Presentation

The role of ICD therapy in heart failure in 2024. What is the holistic approach to treat heart failure?

Congress Session

Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources